The next step in AI drug discovery: Robots

Insilico Medicine is launching its own AI-run robotics lab. The lab has been in the design phase for the past two years and is expected to be fully operational this year. It’s a real world interconnected expansion of Insilico’s end-to-end AI-driven drug discovery platform and will be remotely by its AI system with autonomous guided vehicles running experiments in place of human scientists. These robots will do cell culture, high throughput screening, next generation sequencing, cell imaging, and genomics analysis and prediction. As the robots generate data, that data will feed directly into Insilico's PandaOmics platform, improving the system’s target hypotheses and ability to validate those hypotheses. Picture from video:
Credit: Insilico Medicine

Insilico Medicine to launch a fully automated AI-driven robotics lab later this year.

Insilico Medicine’s end-to-end AI-driven drug discovery platform, Pharma.AI, draws its strength from the quality and quantity of its data. As Insilico scientific advisory board member and Nobel Prize laureate in chemistry Dr. Michael Levitt has said, Insilico’s platform capitalizes on the ability of artificial intelligence to take vast amounts of data from many different components and find patterns and make predictions that can point the way to new life-saving medications.

Insilico began building its platform, using a massive collection of data, beginning in 2014 when the company was founded. PandaOmics™, the target discovery portion of Pharma.AI, uses 1.9 trillion data points drawn from over 10 million samples (such as microarrays, RNA sequencing, and proteomes) and over 40 million documents (including patents, grants, publications, and clinical trial reports). Insilico follows federal grant money from initial experiments to clinical trials, manually inputting when needed, comprising trillions in total. PandaOmics can now not only identify brand new targets for drugs, but it can also predict which targets are likely to be “hot” five years out.

Improving AI with CROs and Pharma Partners

One of the ways that Insilico improves its platform through data is by engaging over 80 contract research organizations who run redundant experiments and create reproducible data sets. The company has 30 internal therapeutic programs in various stages of development, and is turning out preclinical candidates at a record pace. It named 8 preclinical candidates since 2021, including one for COVID-19 and two for cancer in recent months, and its lead candidate for idiopathic pulmonary fibrosis is currently in Phase 1 trials, the first AI-discovered and AI-designed drug to reach this milestone.

Insilico has also expanded its collaborations with pharma through co-development and software licensing deals. Since the launch of PandaOmics™ and Chemistry42™ in late 2020, nine out of the top 20 pharmaceutical companies, as measured by 2020 revenue, have licensed Insilico’s AI platforms. In 2022, Insilico signed multi-asset partnerships with Fosun Pharma and EQRX in January and March, respectively. Notably, Insilico achieved its first major milestone and nominated a preclinical candidate for the QPCTL program for cancer immunotherapy less than 40 days into the strategic collaboration with Fosun Pharma.

Next Step: Robots

Now, Insilico aims to make its end-to-end AI platform even stronger by launching its own AI-run robotics lab. The lab has been in the design phase for the past two years and is expected to be fully operational this year. It’s a real world interconnected expansion of Insilico’s drug discovery platform and will be run autonomously by its AI system with autonomous guided vehicles running experiments in place of human scientists. These robots will do cell culture, high throughput screening, next generation sequencing, cell imaging, and genomics analysis and prediction. As the robots generate data, that data will feed directly into the PandaOmics platform, improving the system’s target hypotheses and ability to validate those hypotheses.

“These robots are faster and more precise than humans,” says Insilico Medicine founder and CEO Alex Zhavoronokov, PhD. “And as they perform experiments they feed the AI system with data, improving the system’s target hypotheses and ability to validate those hypotheses.”

It’s all part of the company’s focus on improving and validating its platform, bringing its lead candidate to Phase 2 trials, and further developing its numerous therapeutic programs. Recently, the company has received additional funding in a $60m Series D round from leading biotech investors, including BHR Partners, Warburg Pincus, B Capital Group, Qiming Venture Partners, BOLD Capital Partners, and Pavilion Capital.

Feng Ren, PhD, Insilico’s Chief Scientific Officer and Head of Global Research and Development who has 15 years of experience working in large pharmaceutical companies and CROs says: “We plan to continue expanding the breadth of the pipeline and enhance our AI and robotics capabilities globally. Our rapidly growing team is composed of talented and experienced scientists in drug discovery with diverse backgrounds and relentless passion for novelty and innovation, and fully committed to developing novel drugs with a sense of urgency for the waiting patients.

A LOOK INSIDE THE NEW AI ROBOTICS LAB (VIDEO)

About Insilico Medicine

Insilico Medicine, a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. Insilico Medicine is delivering breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases and aging-related diseases.

For more information, visit www.insilico.com

For media inquiries, please contact media@insilicomedicine.com

Media Contact

Polina Firsanova
InSilico Medicine
ai@insilico.com
Office: 420-641-6266

www.insilico.com

Media Contact

Polina Firsanova
InSilico Medicine

All latest news from the category: Medical Engineering

The development of medical equipment, products and technical procedures is characterized by high research and development costs in a variety of fields related to the study of human medicine.

innovations-report provides informative and stimulating reports and articles on topics ranging from imaging processes, cell and tissue techniques, optical techniques, implants, orthopedic aids, clinical and medical office equipment, dialysis systems and x-ray/radiation monitoring devices to endoscopy, ultrasound, surgical techniques, and dental materials.

Back to home

Comments (0)

Write a comment

Newest articles

Defects in quartz crystal structure reveal the origin of dust

University of Tübingen research team uses properties of quartz in sediments to study sedi-mentary cycles and climate dynamics. Global warming and a progressively drier climate in many parts of the…

Ultra-thin film creates vivid 3D images with large field of view

Glass-free technique could enable visual features that don’t require special reading devices or illumination. Researchers have developed a new ultra-thin film that can create detailed 3D images viewable under normal…

Artificial photosynthesis can produce food without sunshine

Scientists are developing artificial photosynthesis to help make food production more energy-efficient here on Earth, and one day possibly on Mars. Photosynthesis has evolved in plants for millions of years…

Partners & Sponsors